A Study to Evaluate the Efficacy and Safety of UI022/UI023
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 260 participants.
Also called NCT07600385
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 260 participants
- Sponsor
- Korea United Pharm. Inc.
- Registry
-
NCT07600385
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT07600385. Randomized; double masking; primary purpose treatment. Start 2019-03-12 (actual); primary completion 2022-05-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and Safety of UI022/UI023
- Condition
- Peripheral Arterial Disease
- Intervention (Drug)
- UI022 or UI023 and co-administration of matching placebo
- Intervention (Drug)
- UIC201604 or UIC201801 and co-administration of matching placebo
- Lead sponsor
- Korea United Pharm. Inc.
Record details
- Record id
cardio:ct-nct07600385- Content hash
5fd5f08c3dafd217239fae062faaadbd35a8c48871e4f6583def0c313b5ae0c2